Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shumin Zhen

Nurse Practitioner, Acute Care Pasadena, CA Nurse Practitioner

NPI 1043486491 CMS profile 10978288

625 S Fair Oaks Ave, Ste 215, Pasadena, CA 91105

Open in the dashboard

General payments

$7,950

368 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shumin Zhen of Pasadena, CA is reported in the CMS Open Payments database as having received $7,950 across 368 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,691 49
2024 General $1,505 76
2023 General $1,382 73
2022 General $1,837 87
2021 General $1,534 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shumin Zhen
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Shumin Zhen were reported at $1,691. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Shumin Zhen Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,534 $123 $38–$327 $132
2022 $1,837 $130 $44–$369 $149
2023 $1,382 $144 $49–$410 $160
2024 $1,505 $146 $48–$433 $164
2025 $1,691 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,486 94 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $715 30 payments
  3. AOP Health US, LLC $572 1 payment
  4. Pfizer Inc. $519 30 payments
  5. Amgen Inc. $490 31 payments
  6. AstraZeneca Pharmaceuticals LP $420 23 payments
  7. Alnylam Pharmaceuticals Inc. $403 17 payments
  8. Lexicon Pharmaceuticals, Inc. $388 15 payments
  9. Merck Sharp & Dohme Corporation $373 15 payments
  10. Janssen Pharmaceuticals, Inc $301 16 payments
  11. Other $2,281 96 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,950 368 payments
Products named General payments · program years 2021–2025
  1. LEQVIO $805 56 payments
  2. ENTRESTO Cardiovascular $579 33 payments
  3. Rapiblyk Cardiovascular $572 1 payment
  4. Rapiblyk Cardiovascular $572 1 payment
  5. ELIQUIS $501 29 payments
  6. JARDIANCE $472 20 payments
  7. VERQUVO $455 18 payments
  8. Repatha $438 28 payments
  9. ENTRESTO Cardiology/Vascular Diseases $347 33 payments
  10. AMVUTTRA $322 13 payments
  11. Other $4,185 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$6,540

Medicare's payments for the services billed

Medicare patients

66

Average age 75

Services billed

108

26 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 73%
Arthritis 70%
Heart failure 45%
Atrial fibrillation 44%
Chronic kidney disease 38%
Diabetes 26%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $214
$214 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $188
$188 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $122
$122 — —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $110
$110 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $101
$101 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

368 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record